High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Baghdadi, Muhammad ^a   Endo, Hiraku ^a,b   Takano, Atsushi ^c,d   Ishikawa, Kozo ^a   Kameda, Yosuke ^a   Wada, Haruka ^a   Miyagi, Yohei ^e   Yokose, Tomoyuki ^e   Ito, Hiroyuki ^e   Nakayama, Haruhiko ^e   Daigo, Yataro ^c,d   Suzuki, Nao ^b   Seino, Ken Ichiro ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e KANAGAWA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; CSF1 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; INTERLEUKIN-34, HUMAN;

ADULT; AGED; CANCER STAGING; DISEASE EXACERBATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL ANALYSIS; TISSUE MICROARRAY; TUMOR MICROENVIRONMENT; UPREGULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKINS; LUNG NEOPLASMS; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MICROENVIRONMENT; UP-REGULATION;

EID: 85040465329     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-18796-8     Document Type: Article

References (35)

1. Miller, K. D. et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J. Clin. 66, 271-89 (2016).
2. Bepler, G. et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J. Clin. Oncol. 24, 4731-7 (2006).
3. Lee, J. J. et al. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer 70, 205-10 (2010).
4. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-500 (2004).
5. Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLOS Med. 2, e73 (2005).
6. Eberhard, D. A. et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900-9 (2005).
7. Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49-61 (2014).
8. De Palma, M. & Lewis, C. E. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 223, 277-86 (2013).
9. Ruffell, B. & Coussens, L. M. Macrophages and therapeutic resistance in cancer. Cancer Cell 27, 462-72 (2015).
10. Lippitz, B. E. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 14, e218-28 (2013).
11. Allavena, P., Sica, A., Solinas, G., Porta, C. & Mantovani, A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 66, 1-9 (2008).
12. Mantovani, A., Schioppa, T., Porta, C., Allavena, P. & Sica, A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 25, 315-22 (2006).
13. Condeelis, J. & Pollard, J. W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124, 263-6 (2006).
14. Droin, N. & Solary, E. Editorial: CSF1R, CSF-1, and IL-34, a "menage a trois" conserved across vertebrates. J. Leukoc. Biol. 87, 745-7 (2010).
15. Nakamichi, Y., Udagawa, H. & Takahashi, N. IL-34 and CSF-1: similarities and differences. J. Bone Miner. Metab. 31, 486-95 (2013).
16. Chihara, T. et al. IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation. Cell Death Differ. 17, 1917-27 (2010).
17. Ségaliny, A. I. et al. IL-34 and M-CSF form a novel heteromeric cytokine and regulate the M-CSF receptor activation and localization. Cytokine 76, 170-81 (2015).
18. Chockalingam, S. & Ghosh, S. S. Macrophage colony-stimulating factor and cancer: a review. Tumour Biol. 35, 10635-44 (2014).
19. Baghdadi, M. et al. Chemotherapy-Induced IL34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells. Cancer Res. 76, 6030-6042 (2016).
20. McDermott, R. S. et al. Circulating macrophage colony stimulating factor as a marker of tumour progression. Eur. Cytokine Netw. 13, 121-7 (2002).
21. Scholl, S. M. et al. Circulating levels of the macrophage colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study. Breast Cancer Res. Treat. 39, 275-83 (1996).
22. Lin, H. et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science 320, 807-11 (2008).
23. Stanley, E. R. & Chitu, V. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb. Perspect. Biol. 6, a021857 (2014).
24. Hung, J. Y. et al. Colony-stimulating factor 1 potentiates lung cancer bone metastasis. Lab. Invest. 94, 371-81 (2014).
25. Patsialou, A. et al. Autocrine CSF1R signaling mediates switching between invasion and proliferation downstream of TGFbeta in claudin-low breast tumor cells. Oncogene 34, 2721-31 (2015).
26. Achkova, D. & Maher, J. Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer. Biochem. Soc. Trans. 44, 333-41 (2016).
27. Fabriek, B. O. & Dijkstra, C. D. & Van den Berg, T. K. The macrophage scavenger receptor CD163. Immunobiology 210, 153-60 (2005).
28. Heusinkveld, M. & der Burg, V. S.H. Identification and manipulation of tumor associated macrophages in human cancers. J. Transl. Med. 9, 216 (2011).
29. Medrek, C., Pontén, F., Jirström, K. & Leandersson, K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 12, 306 (2012).
30. Castells, M. et al. Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int. J. Mol. Sci. 13, 9545-71 (2012).
31. Naugler, W. E. & Karin, M. NF-kappaB and cancer-identifying targets and mechanisms. Curr. Opin. Genet. Dev. 18, 19-26 (2008).
32. Baud'huin, M. et al. Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis. J. Pathol. 221, 77-86 (2010).
33. Cioce, M. et al. Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation. Cell Death Dis. 5, e1167 (2014).
34. Baghdadi, M., Endo, H., Tanaka, Y., Wada, H. & Seino, K. Interleukin 34, from pathogenesis to clinical applications. Cytokine 99, 139-147 (2017).
35. Maniecki, M. B. et al. Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int. J. Cancer 131, 2320-31 (2012).